PROCEPT BioRobotics (PRCT) experienced a significant pre-market plunge of 23.13% on Thursday, following disappointing quarterly results and subsequent analyst price target reductions.

The sharp decline comes after the company released its fourth-quarter 2025 financial results, which fell short of analyst expectations. PROCEPT reported a quarterly loss per share of $(0.53), missing the consensus estimate of $(0.32) by a wide margin. Revenue for the quarter was $76.383 million, also below the estimated $94.137 million. CEO Larry Wood stated that the revenue shortfall was due to strategic actions including a commercial organization realignment, the elimination of end-of-quarter purchasing incentives, and a more disciplined handpiece pricing strategy.

Following the earnings report, multiple analysts cut their price targets on the stock. TD Cowen maintained a Buy rating but reduced its target to $34 from $50, Jefferies cut its target to $30 from $39, and Leerink Partners slashed its target to $30 from $55. These downgrades contributed to the selling pressure in pre-market trading as investors reassessed the company's near-term prospects.